Veravas
Charleston, US · Founded 2017 · Delaware corporation
Veravas develops the patented VeraBIND diagnostic platform that reduces interference in laboratory testing to measure hard-to-detect biomarkers, with a current application in blood-based early detection of tau pathology associated with Alzheimer's disease. It provides tests and sample pre-treatment solutions aimed at researchers and diagnostic labs for improved assay sensitivity and biomarker detection.</parameter> <parameter name="founders">[]
Founders & leadership
Veravas was founded in 2017 by John Forrest and Joshua Soldo.
JF
John ForrestinFounder and Executive ChairmanJohn Forrest is Co-Founder and CEO of Veravas, which develops the VeraBIND diagnostic platform to measure biomarkers associated with neurodegenerative diseases. He has over 30 years of experience in healthcare IT and founding companies focused on diagnostic testing and healthcare information access.
JS
Joshua SoldoinFounder
FA
Frederick Allen BaumbachNamed on SEC filing
CE
Carroll E. Streetman, Jr.Named on SEC filing
Reported raises · per SEC filings
Form D private placements$21.7M disclosed across 3 rounds · 2019–2024
▶$20.6MraisedApr 2024 · 138 investors · Other Health CareRule 506(b)
▶$20.6MraisedApr 2024 · 138 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeremy CooteDirector
- James KyleDirector
- John ForrestExecutive Officer, Director, Promoter
- Luc VanhalExecutive Officer
- Will KikerDirector
- Offering amount
- $26.4M
- Amount sold
- $20.6M
- Proceeds to insiders
- $625K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$775KraisedMar 2023 · 12 investors · Other Health CareRule 506(c)
▶$775KraisedMar 2023 · 12 investors · Other Health Care
Rule 506(c)Officers, directors & promoters on the filing
- John ForrestExecutive Officer
- Offering amount
- $50M
- Amount sold
- $775K
- Minimum investment
- $25K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$375KraisedOct 2019 · 6 investors · Other Health CareRule 506(b)
▶$375KraisedOct 2019 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Frederick Allen BaumbachExecutive Officer
- John Michael ForrestExecutive Officer, Director, Promoter
- Carroll E. Streetman, Jr.Executive Officer
- Offering amount
- $2M
- Amount sold
- $375K
- Proceeds to insiders
- $160K
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Veratx9 shared keywordsVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Verana Health5 shared keywordsVerana Health aggregates de-identified clinical data from a network of over 20,000 physicians in ophthalmology, urology, and neurology to power real-world evidence, clinical trial enablement, and quality reporting for pharmaceutical companies and healthcare providers using AI and machine learning.
Verastem5 shared keywordsVerastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.
Veras5 shared keywordsVeras builds a workforce platform for the long-term and post-acute care industry, handling shift-based scheduling, CMS compliance, and frontline care workforce management. It targets care operators, aiming to reduce labor costs and improve staff retention and quality of care.
Companies competing with Veravas for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Veravas do?
- Veravas develops the patented VeraBIND diagnostic platform that reduces interference in laboratory testing to measure hard-to-detect biomarkers, with a current application in blood-based early detection of tau pathology associated with Alzheimer's disease. It provides tests and sample pre-treatment solutions aimed at researchers and diagnostic labs for improved assay sensitivity and biomarker detection.</parameter> <parameter name="founders">[]
- Who founded Veravas?
- Veravas was founded by John Forrest, Joshua Soldo in 2017.
- How much funding has Veravas raised?
- Veravas has disclosed $21.7M raised across 3 rounds.
- Where is Veravas headquartered?
- Veravas is headquartered in Charleston, US.